Evidence map›Paper›PMID 38678160›Full record

ArticleGene therapy2024

AAV-vectored expression of monospecific or bispecific monoclonal antibodies protects mice from lethal Pseudomonas aeruginosa pneumonia.

Jordyn A Lopes, Nicole E Garnier, Yanlong Pei, Jacob G E Yates, Elena S B Campbell, Melanie M Goens, Madison E Hughes, Amira D Rghei, Brenna A Y Stevens, Matthew M Guilleman and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Gene therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. In vivo mRNA expression of a multi-mechanistic mAb combination protects against Staphylococcus aureus infection.Molecular therapy : the journal of the American Society of Gene Therapy · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Jordyn A LopesDepartment of Pathobiology, University of Guelph, Guelph, ON, N1G 2W1, Canada.
Nicole E GarnierDepartment of Molecular and Cellular Biology, University of Guelph, Guelph, ON, N1G 2W1, Canada.
Yanlong PeiDepartment of Pathobiology, University of Guelph, Guelph, ON, N1G 2W1, Canada.
Jacob G E YatesDepartment of Pathobiology, University of Guelph, Guelph, ON, N1G 2W1, Canada.
Elena S B CampbellDepartment of Pathobiology, University of Guelph, Guelph, ON, N1G 2W1, Canada.
Melanie M GoensDepartment of Pathobiology, University of Guelph, Guelph, ON, N1G 2W1, Canada.
Madison E HughesDepartment of Pathobiology, University of Guelph, Guelph, ON, N1G 2W1, Canada.
Amira D RgheiDepartment of Pathobiology, University of Guelph, Guelph, ON, N1G 2W1, Canada.
Brenna A Y StevensDepartment of Pathobiology, University of Guelph, Guelph, ON, N1G 2W1, Canada.
Matthew M GuillemanDepartment of Pathobiology, University of Guelph, Guelph, ON, N1G 2W1, Canada.
Brad ThompsonAvamab Pharma Inc., 120, 4838 Richard Road SW, Calgary, AB, T3E 6L1, Canada.
Cezar M KhursigaraDepartment of Molecular and Cellular Biology, University of Guelph, Guelph, ON, N1G 2W1, Canada.
Leonardo SustaDepartment of Pathobiology, University of Guelph, Guelph, ON, N1G 2W1, Canada.ORCID 0000-0002-4578-6145
Sarah K WoottonDepartment of Pathobiology, University of Guelph, Guelph, ON, N1G 2W1, Canada. kwootton@uoguelph.ca.ORCID 0000-0002-5985-2406
University of Guelph · CARichard Wolf (Germany) · DE

Funding

Gouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Santé du Canada) 202109PJ4-474300-VVP-CEHA-140973Gouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Santé du Canada) PJT 156111Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada (Conseil de Recherches en Sciences Naturelles et en Génie du Canada) 499834
6 · The paper itself

Abstract

Pseudomonas aeruginosa poses a significant threat to immunocompromised individuals and those with cystic fibrosis. Treatment relies on antibiotics, but persistent infections occur due to intrinsic and acquired resistance of P. aeruginosa towards multiple classes of antibiotics. To date, there are no licensed vaccines for this pathogen, prompting the urgent need for novel treatment approaches to combat P. aeruginosa infection and persistence. Here we validated AAV vectored immunoprophylaxis as a strategy to generate long-term plasma and mucosal expression of highly protective monoclonal antibodies (mAbs) targeting the exopolysaccharide Psl (Cam-003) and the PcrV (V2L2MD) component of the type-III secretion system injectosome either as single mAbs or together as a bispecific mAb (MEDI3902) in a mouse model. When administered intramuscularly, AAV-αPcrV, AAV-αPsl, and AAV-MEDI3902 significantly protected mice challenged intranasally with a lethal dose of P. aeruginosa strains PAO1 and PA14 and reduced bacterial burden and dissemination to other organs. While all AAV-mAbs provided protection, AAV-αPcrV and AAV-MEDI3902 provided 100% and 87.5% protection from a lethal challenge with 4.47 × 10

Indexed as

Antibodies, MonoclonalDependovirusGenetic VectorsPseudomonas aeruginosaPseudomonas InfectionsAnimalsAntibodies, BispecificAntigens, BacterialBacterial ToxinsDisease Models, AnimalFemaleHumansMiceMice, Inbred C57BLPneumonia, BacterialPore Forming Cytotoxic ProteinsAntibodies, BispecificAntibodies, MonoclonalAntigens, Bacterialantigen V, PseudomonasBacterial ToxinsPore Forming Cytotoxic Proteins

Identifiers

PMID38678160
OpenAlexW4395693065

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.